This study, called the PULSO Trial, is looking at a new way to give radiation therapy for esophageal cancer. It compares standard radiation therapy with a technique called Pulsed Low-Dose-Rate (PLDR) radiation. PLDR radiation delivers the same total dose but in small pulses with pauses in between, which may be less harmful to healthy tissues while still killing cancer cells. Participants will also receive chemotherapy, either modified FLOT or modified FOLFOX-6 before radiation, and carboplatin/paclitaxel weekly during radiation. The study wants to see if PLDR radiation leads to fewer problems like difficulty swallowing (esophagitis) during and after treatment. You may be able to join if you are 18 or older and have Stage II-IVb adenocarcinoma of the esophagus. The study is currently unclear on its recruitment status and plans to enroll 50 people.

Study design

This is a Phase 2, prospective, randomized, open-label study comparing two radiation approaches. It plans to enroll 50 participants.

What's involved

Participants will receive 2-4 months of induction chemotherapy, followed by chemoradiation therapy. Surgery may also be part of your treatment plan.

Compensation

Not stated in the trial record.

Follow-up

The study will track new or increased narcotic prescriptions and oral intake for up to 6 weeks after radiation treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.